2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Papilloma: new trials by email Literature Review of Papilloma trials Research Report on Papilloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) Bevacizumab - Respiratory Tract Diseases, Neoplasms | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2023-08-02 | 2026-10-29 |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment - Oropharynx Cancer | Phase 2 | Recruiting | Heath Skinner | 150 | 2022-07-20 | 2026-07-21 |
| Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Propranolol - Recurrent Respiratory Papillomatosis | Phase 2 / Phase 3 | Withdrawn | Massachusetts Eye and Ear Infirmary | 2010-01-01 | 2013-11-21 | |
| Treatment of Oral Warts in HIV+ Patients Interferon-alpha, placebo - Papillomatosis, HIV Infections | Phase 2 | Completed | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | 59 | 2007-02-01 | 2011-09-16 |
| Celebrex (Celecoxib) Treatment of Laryngeal Papilloma Celebrex, PDL, CO2 laser or microsurgery - Laryngeal Papilloma | Phase 2 | Terminated | Boston University | 10 | 2005-05-01 | 2012-08-31 |
| A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis SGN-00101 - Papilloma, Recurrent Respiratory Papillomatosis | Phase 2 | Completed | Nventa Biopharmaceuticals Corporation | 27 | 2001-11-01 | 2007-06-27 |
DNA Virus Infections (2) · Neoplasms, Glandular and Epithelial (2) · Papillomavirus Infections (2) · Recurrent respiratory papillomatosis (2) · Tumor Virus Infections (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Squamous Cell (1) · Disease Attributes (1) · HIV Infections (1) · Head and Neck Neoplasms (1) · Infections (1) · Laryngeal papillomatosis (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Squamous Cell (5) · Neoplasms, Glandular and Epithelial (4) · Communicable Diseases (3) · Genital Diseases (3) · Sexually Transmitted Diseases (3) · Sexually Transmitted Diseases, Viral (3) · Urogenital Diseases (3) · Infections (2) · Pathological Conditions, Signs and Symptoms (2) · Virus Diseases (2) · Blood-Borne Infections (1) · Carcinoma (1) · DNA Virus Infections (1)
Bevacizumab (1) · Carboplatin (1) · Celecoxib (1) · Cisplatin (1) · Interferon-alpha (1) · Laser Therapy (1) · Lasers, Gas (1) · Maltose (1) · Microsurgery (1) · Propranolol (1) · Radiotherapy, Intensity-Modulated (1) · Sugars (1)
Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1) · Boston University (1) · Heath Skinner (1) · Massachusetts Eye and Ear Infirmary (1) · National Cancer Institute (NCI) (1) · Nventa Biopharmaceuticals Corporation (1)
United States (5)
Christopher Hartnick, MD (1) · Deborah Greenspan, BDS, DSc (1) · Heath Skinner, MD, PhD (1) · Scott M Norberg, D.O. (1) · Wang Zhi, M.D (1)
R01DC006617 (1)